StockData
Avenue Therapeutics, Inc. logo

Avenue Therapeutics, Inc. (ATXI) company profile

ATXIOTCPharmaceutical PreparationsFiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Nov 6, 2026Score 4/30
$0.43+0.00 (0.00%)

Close on Oct 16, 2026Market cap $1.42MP/E –Yield –

About Avenue Therapeutics

Pharmaceutical Preparations, SIC 2834

Avenue Therapeutics, Inc. is a specialty pharmaceutical company focused on developing and commercializing therapies for neurologic conditions. The company's primary product candidates include ATX-04, an orally administered selective beta-2 adrenergic agonist under development for the treatment of Pompe disease as an adjunct to enzyme replacement therapy, and intravenous tramadol, a Schedule IV opioid candidate designed for the management of postoperative acute pain in hospital or postsurgical settings. Avenue previously held rights to BAER-101 for epilepsy and panic disorders before divesting the program. Its prospective target end users are treating physicians, surgical practitioners, and patients suffering from rare lysosomal storage disorders or acute postsurgical pain.

The business operates as a majority-controlled subsidiary of Fortress Biotech, Inc. Its clinical and regulatory initiatives primarily target the United States and European healthcare markets, and the company holds worldwide licensing rights for ATX-04 as well as licensing rights to develop and commercialize intravenous tramadol. The provided report does not state the specific location of its corporate headquarters.

Summary of the business section of Avenue Therapeutics's latest annual report, written by StockData.

Company profile

Company

Legal name
Avenue Therapeutics, Inc.
Headquarters
Bay Harbor Islands, FL
Address
1111 Kane Concourse, Suite 301 33154
Phone
(781) 652-4500
Employees
1, Dec 31, 2025
Industry
Pharmaceutical Preparations
Incorporated in
Delaware
Fiscal year ends
December 31
Auditor
KPMG LLP, New York, NY

Stock & identifiers

Ticker
ATXI
Exchange
OTC
IPO date
Jun 27, 2017
Shares outstanding
3M, Aug 4, 2026
Public float
$571.90K, Jun 30, 2025
Filer category
Non-accelerated filer<br>Smaller reporting company
Stock splits
1-for-75 reverse, Apr 26, 2024; 1-for-15 reverse, Sep 23, 2022; 1-for-3 reverse, Aug 11, 2017
SEC CIK
1644963
CUSIP
05360L403
ISIN
US05360L4032
FIGI
BBG00GLTS4V4
Share class FIGI
BBG00GLTS5K3
LEI
549300IN52C2XAYTBO53
EIN
47-4113275

Executives and directors

Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years

NamePositionShares owned
Neil HerskowitzDirector97

CEO pay and shareholder return

Pay versus performance table from the proxy statement

Fiscal yearCEO total payCEO pay actually paidOther executives (avg)Value of $100 investedPeer group
FY2024
PEO1
$840.10K$728.60K$155.35K$0–
FY2024
PEO2
$0$0$155.35K$0–
FY2024
PEO3
$155.35K$115.87K$155.35K$0–
FY2023
PEO1
$1.21M$659.20K$260.00K$0–
FY2023
PEO2
$0$0$260.00K$0–
FY2023
PEO3
$0$0$260.00K$0–

“Actually paid” adjusts reported pay for changes in the value of equity awards. Shareholder return assumes $100 invested at the start of the measurement period, as disclosed by the company.

Executive compensation, fiscal 2024

Summary compensation table from the latest proxy statement

ExecutiveSalaryStock awardsOtherTotalvs. prior year
Alexandra MacLean
Chief Executive Officer
$420.00K$406.30K$13.80K$840.10K-31%
David Jin
Interim Chief Financial Officer and Chief Operating Officer
–$155.35K–$155.35K-40%

Stock and option awards are grant-date fair values, not realized pay. “Other” includes pension value changes and all other compensation. Source proxy statement.

Employees

Headcount reported in annual reports

“As of December 31, 2025, we had 1 full-time employee.”

Corporate history

Events identified from SEC filings

DateEventDetails
Jul 18, 2025DelistingNotice of delisting from exchange (Form 25)
Apr 30, 2025Acquisition / saleCompletion of acquisition or disposition of assets (8-K Item 2.01)
Mar 17, 2025Listing noticeNotice of delisting or failure to satisfy a listing rule (8-K Item 3.01)
Nov 29, 2024Listing noticeNotice of delisting or failure to satisfy a listing rule (8-K Item 3.01)
Mar 29, 2024Listing noticeNotice of delisting or failure to satisfy a listing rule (8-K Item 3.01)
Nov 24, 2023Listing noticeNotice of delisting or failure to satisfy a listing rule (8-K Item 3.01)
Sep 28, 2023Listing noticeNotice of delisting or failure to satisfy a listing rule (8-K Item 3.01)
May 22, 2023Listing noticeNotice of delisting or failure to satisfy a listing rule (8-K Item 3.01)
Jan 25, 2023Auditor changeChange in certifying accountant (8-K Item 4.01)
Nov 8, 2022Acquisition / saleCompletion of acquisition or disposition of assets (8-K Item 2.01)
Sep 30, 2022Listing noticeNotice of delisting or failure to satisfy a listing rule (8-K Item 3.01)
Aug 12, 2022Listing noticeNotice of delisting or failure to satisfy a listing rule (8-K Item 3.01)
May 25, 2022Listing noticeNotice of delisting or failure to satisfy a listing rule (8-K Item 3.01)
May 16, 2022Listing noticeNotice of delisting or failure to satisfy a listing rule (8-K Item 3.01)
Mar 8, 2022Listing noticeNotice of delisting or failure to satisfy a listing rule (8-K Item 3.01)
Feb 11, 2022Listing noticeNotice of delisting or failure to satisfy a listing rule (8-K Item 3.01)
Sep 3, 2021Listing noticeNotice of delisting or failure to satisfy a listing rule (8-K Item 3.01)
Jan 8, 2021Listing noticeNotice of delisting or failure to satisfy a listing rule (8-K Item 3.01)
Apr 11, 2019Listing noticeNotice of delisting or failure to satisfy a listing rule (8-K Item 3.01)
Dec 21, 2018Merger voteDefinitive merger proxy statement
Jun 14, 2017ListingRegistration of securities on an exchange (Form 8-A)

See a number that looks wrong?